

## Clinicians ACD Pro Forma

### Expert Views on NICE Appraisal Consultation Document (ACD)

#### Ritiximab for first line treatment of stage 111-1V follicular lymphoma (review of TA110)

To be returned to [REDACTED] on or by: 26<sup>th</sup> September 2011

From: Dr Anne Parker

#### Comments on the NICE ACD

Your comments are forwarded to NICE as part of their formal consultation process on this technology assessment. They are also used by NHS Quality Improvement Scotland to inform advice issued to NHSScotland on the applicability of the guidance in Scotland. We are particularly interested in receiving from you a Scottish perspective on the guidance, and the implications of implementing this guidance in NHSScotland

The headings below are provided to guide your commenting. Please feel free to cover any other points which you think should be raised.

1. Do you consider that all the relevant evidence has been taken into account? *If not, what evidence do you consider has been omitted, and what are the implications of this omission on the results?*  
All the available published info has been taken into account. I am disappointed that they have restricted the use to certain chemotherapy regimens as I believe that this disadvantages the elderly where few clinical trials are carried out. I think rituximab should be available with first line chlorambucil
2. Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence? *If not, in which areas do you consider that the summaries are not reasonable interpretations?* Yes
3. Are the provisional recommendations of the Appraisal Committee sound and do they constitute a suitable basis for the preparation of guidance to the NHS? *If not, why do you consider that the recommendations are not sound?* They are reasonable
4. Are the patient pathways and treatment options described in the assessment applicable to NHSScotland? *If not, how do they differ in Scotland?* Yes
5. Would the provisional recommendations change the patient pathways and/or patient numbers in NHSScotland? *If so, please describe what these changes would be.*  
Probably no major impact as I believe that most centres are using Rituximab with regimens other than RCVP
6. Do you think there is any reason why this provisional guidance would not be as valid in Scotland as it is in England and Wales? *If yes, please explain why this is the case.* No
7. Please add any other information which you think would be useful to NICE or helpful in guiding the Scottish response to this assessment none relevant that I am aware of

**Clinicians ACD Pro Forma**

**Expert Views on NICE Appraisal Consultation Document (ACD)**

**Ritiximab for first line treatment of stage 111-1V follicular lymphoma  
(review of TA110)**

**To be returned to [REDACTED] [REDACTED] on or by: 26<sup>th</sup> September 2011**

**From: Dr Anne Parker**

It is the view of NHS QIS that its activities should be open and transparent. In compliance with the Freedom of Information (Scotland) Act, NHS QIS will either place comments received in this consultation in the public domain or make them available as necessary.

Thank you for completing this proforma

Please return to:

